Akebia Therapeutics Inc. (AKBA) Financial Statements (2025 and earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments39,49941,96142,92546,52953,57256,953
Cash and cash equivalents39,49941,96142,92546,52953,57256,953
Receivables29,76526,62039,29022,59219,57217,781
Inventory, net of allowances, customer advances and progress billings23,87225,53215,69118,44220,90520,604
Inventory23,87225,53215,69118,44220,90520,604
Prepaid expense     15,600 
Other current assets7,3294,8135,754   
Other undisclosed current assets11,63214,01814,48922,0398,79825,381
Total current assets:112,097112,944118,149109,602118,447120,719
Noncurrent Assets
Operating lease, right-of-use asset10,36011,39912,41613,41414,39127,958
Property, plant and equipment2,8953,2653,6294,0234,4194,816
Intangible assets, net (including goodwill)77,06586,07695,086104,097113,107118,127
Goodwill59,04459,04459,04459,04459,04455,053
Intangible assets, net (excluding goodwill)18,02127,03236,04245,05354,06363,074
Other noncurrent assets17,77911,79312,4233,8623,3485,238
Total noncurrent assets:108,099112,533123,554125,396135,265156,139
TOTAL ASSETS:220,196225,477241,703234,998253,712276,858
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities64,00465,79282,37071,70268,18458,944
Accounts payable10,10711,88214,6359,03811,77612,577
Accrued liabilities53,89753,91067,73562,66456,40846,367
Deferred revenue 43,296695    
Debt   17,5008,00024,00024,000
Total current liabilities:107,30066,48799,87079,70292,18482,944
Noncurrent Liabilities
Long-term debt and lease obligation38,03130,14517,18334,61318,48626,296
Long-term debt, excluding current maturities38,03130,14517,18334,61318,48626,296
Liabilities, other than long-term debt15,50062,67861,12862,93871,91883,357
Deferred revenue  43,29643,29643,29643,29643,296
Other liabilities6,5576,7718,8859,41517,14212,643
Operating lease, liability6,2997,6368,94710,22711,48027,418
Derivative instruments and hedges, liabilities2,6444,975    
Other undisclosed noncurrent liabilities93,11993,42594,10697,16797,93198,613
Total noncurrent liabilities:146,650186,248172,417194,718188,335208,266
Total liabilities:253,950252,735272,287274,420280,519291,210
Equity
Equity, attributable to parent(33,754)(27,258)(30,584)(39,422)(26,807)(14,352)
Common stock222222
Additional paid in capital1,601,7551,599,6691,578,3581,570,1341,568,2601,564,770
Accumulated other comprehensive income666666
Accumulated deficit(1,635,517)(1,626,935)(1,608,950)(1,609,564)(1,595,075)(1,579,130)
Total equity:(33,754)(27,258)(30,584)(39,422)(26,807)(14,352)
TOTAL LIABILITIES AND EQUITY:220,196225,477241,703234,998253,712276,858

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues43,64832,60756,19642,04656,37640,127
Cost of revenue
(Cost of Goods and Services Sold)
(17,047)(11,605)(18,665)(18,009)(17,284)(19,484)
Gross profit:26,60121,00237,53124,03739,09220,643
Operating expenses(35,326)(35,938)(36,157)(37,073)(48,088)(45,581)
Operating income (loss):(8,725)(14,936)1,374(13,036)(8,996)(24,938)
Nonoperating income (expense)(39)95(167)(43)(10)282
Loss on contract termination   (825)   
Other nonoperating income (expense)(39)95658(43)(10)282
Interest and debt expense  (517)    
Income (loss) from continuing operations before equity method investments, income taxes:(8,764)(15,358)1,207(13,079)(9,006)(24,656)
Other undisclosed income (loss) from continuing operations before income taxes182(2,627)(6,556)   
Net loss:(8,582)(17,985)(5,349)(13,079)(9,006)(24,656)
Other undisclosed net income (loss) attributable to parent   5,963(1,410)(2,166)(1,561)
Net income (loss) available to common stockholders, diluted:(8,582)(17,985)614(14,489)(11,172)(26,217)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(8,582)(17,985)(5,349)(13,079)(9,006)(24,656)
Comprehensive loss:(8,582)(17,985)(5,349)(13,079)(9,006)(24,656)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   5,963(1,410)(2,166)(1,561)
Comprehensive income (loss), net of tax, attributable to parent:(8,582)(17,985)614(14,489)(11,172)(26,217)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: